Previous close | 3.0000 |
Open | 3.0000 |
Bid | 0.7000 |
Ask | 5.0000 |
Strike | 15.00 |
Expiry date | 2024-10-18 |
Day's range | 3.0000 - 3.0000 |
Contract range | N/A |
Volume | |
Open interest | 21 |
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.